BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 9811522)

  • 1. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
    Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study.
    Englund JA; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Anderson EL
    Pediatrics; 1994 Jan; 93(1):37-43. PubMed ID: 8265321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA; King J; Law B; Mills E; Willems P
    Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two trials of an acellular DTP vaccine in comparison with a whole-cell DTP vaccine in infants: evaluation of two PT doses and two vaccination schedules.
    Just M; Kanra G; Bogaerts H; Berger R; Ceyhan M; Pêtre J
    Dev Biol Stand; 1991; 73():275-83. PubMed ID: 1778319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of diphtheria-tetanus-two component acellular pertussis vaccines in United States and Japanese infants at 2, 4, and 6 months of age.
    Rothstein EP; Kamiya H; Nii R; Matsuda T; Bernstein HH; Long SS; Hosbach PH; Meschievitz CK
    Pediatrics; 1996 Feb; 97(2):236-42. PubMed ID: 8584384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
    Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
    Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.
    Halperin SA; Eastwood B; Barreto L; Mills E; Blatter M; Reisinger K; Bader G; Keyserling H; Roberts EA; Guasparini R
    Scand J Infect Dis; 1995; 27(3):279-87. PubMed ID: 8539554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine.
    Pichichero ME; Green JL; Francis AB; Marsocci SM; Murphy AM; Buscarino C
    Scand J Infect Dis; 1996; 28(2):159-63. PubMed ID: 8792483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines.
    Rennels MB; Reed GF; Decker MD; Edwards KM; Pichichero ME; Deloria MA; Englund JA; Anderson EL; Steinhoff MC; Deforest A
    Pediatrics; 1995 Sep; 96(3 Pt 2):576-9. PubMed ID: 7659479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
    Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
    Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
    Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
    Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diphtheria and tetanus toxoids and pertussis vaccine adsorbed (DTP): response to varying immunizing dosage and schedule.
    Barkin RM; Samuelson JS; Gotlin LP
    Dev Biol Stand; 1985; 61():297-307. PubMed ID: 2872117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.